Share on StockTwits

Valeant Pharmaceuticals Intl (NYSE:VRX) issued its quarterly earnings data on Thursday. The company reported $1.76 EPS for the quarter, beating the Thomson Reuters consensus estimate of $1.72 by $0.04, StockRatingsNetwork reports. The company had revenue of $1.85 billion for the quarter, compared to the consensus estimate of $1.04 billion. During the same quarter in the prior year, the company posted $1.30 earnings per share. The company’s quarterly revenue was up 76.6% on a year-over-year basis.

VRX has been the subject of a number of recent research reports. Analysts at Jefferies Group reiterated a “buy” rating on shares of Valeant Pharmaceuticals Intl in a research note on Thursday. They now have a $153.00 price target on the stock. Finally, analysts at JPMorgan Chase & Co. reiterated an “overweight” rating on shares of Valeant Pharmaceuticals Intl in a research note on Wednesday, April 23rd. They now have a $180.00 price target on the stock. One investment analyst has rated the stock with a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $146.41.

Shares of Valeant Pharmaceuticals Intl (NYSE:VRX) traded up 0.70% on Thursday, hitting $134.28. 301,081 shares of the company’s stock traded hands. Valeant Pharmaceuticals Intl has a 1-year low of $72.25 and a 1-year high of $153.10. The stock has a 50-day moving average of $130.0 and a 200-day moving average of $125.3. The company’s market cap is $44.966 billion.

Valeant Pharmaceuticals International, Inc, formerly Biovail Corporation, is a multinational, specialty pharmaceutical company that develops, manufactures and markets a range of pharmaceutical products.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.